Advancing hepatology through innovation and integration:iLIVER''s vision for 2026OA
Liver diseases continue to impose a substantial and evolving burden on global health up to 2026,characterised by a wide clinical spectrum and increasing therapeutic complexity.Liver cancer remains the sixth most common malignancy and the third leading cause of cancer-related mortality worldwide,with hepatocellular carcinoma(HCC)accounting for nearly 75%of all primary liver cancers.1 Although sustained viral hepatitis control programs have stabilized or reduced virus-related HCC incidence in many regions,its epidemiological profile is undergoing a marked transition,with metabolic dysfunction-associated steatotic liver disease(MASLD)increasingly contributing to HCC cases,driven by global obesity and metabolic syndrome epidemics.
Zu-Chao Du;Ke-Chun Wang;Ming-Da Wang;Lei Cai;Jian-Hong Zhong;Tian Yang
Department of Hepatobiliary Surgery,The First Affiliated Hospital,Henan University,Kaifeng 475000,Henan,ChinaDepartment of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital,Naval Medical University,Shanghai 200438,ChinaDepartment of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital,Naval Medical University,Shanghai 200438,ChinaInstitute of Hepatopancreatobiliary Surgery,Chongqing General Hospital,Chongqing University,Chongqing 401147,ChinaDepartment of Hepatobiliary Surgery,Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,Guangxi,ChinaDepartment of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital,Naval Medical University,Shanghai 200438,China
医药卫生
Hepatocellular carcinomaArtificial intelligenceLiquid biopsyConversion therapyMetabolic dysfunction-associated steatotic liver diseasePrecision medicine
《iLIVER》 2026 (1)
P.1-3,3
评论